Tech Center 1600 • Art Units: 1621 1626 1629
This examiner grants 58% of resolved cases
SHIM, DAVID M. is an examiner in Tech Center 1600 and Art Unit 1621. The data includes 96 resolved cases. The allowance rate is 58.3 percent, which reflects the frequency of grants for applications assigned to this examiner. Practitioners can use the 58.3 percent allowance rate to assess the likelihood of a positive outcome during prosecution. The 96 resolved cases provide a data set for analyzing the examiner's historical patterns in this specific technological area.
The interview lift is 58.3 percent. This metric indicates that the allowance rate is higher when an interview is conducted compared to the baseline rate of 58.3 percent. An interview lift of 58.3 percent suggests that direct communication is an exceptionally effective strategy for overcoming rejections. Practitioners should prioritize scheduling an interview to clarify technical issues or to negotiate claim scope. This 58.3 percent lift shows a clear benefit to verbal engagement with the examiner.
The median days to allowance is 1078. This number represents the middle point of the time required to reach a grant. A median of 1078 days provides a benchmark for the expected duration of the examination process. The combination of the 58.3 percent allowance rate and the 1078-day pendency defines the current prosecution environment for this examiner. These figures help applicants to manage expectations regarding both the timing and the probability of success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18735506 | FORMULATIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | Non-Final OA | Northwestern University |
| 18721947 | AN INJECTABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES IN ANIMALS | Non-Final OA | Intervet Inc. |
| 18845718 | NOVEL TAFAMIDIS SYNTHESIS METHOD | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18850466 | TYK2 INHIBITORS AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18646178 | COMPOUNDS | Non-Final OA | GlaxoSmithKline Intellectual Property Development Limited |
| 18853933 | EGFR INHIBITORS | Non-Final OA | Blueprint Medicines Corporation |
| 18696960 | PIKFYVE KINASE INHIBITOR | Non-Final OA | HANMI PHARM. CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy